Histone Lysine N Methyltransferase EZH2 – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) – Pipeline Review, H1 2020’, provides in depth analysis on Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Infectious Disease, Gastrointestinal and Hematological Disorders under development targeting Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)

– The report reviews Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics and enlists all their major and minor projects

– The report assesses Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Constellation Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Domainex Ltd

Epizyme Inc

Eternity Bioscience Inc

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

Ionis Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

Kainos Medicine Inc

OncoFusion Therapeutics Inc

Pfizer Inc

Transgene Biotek Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC

2.1.1.43) – Overview

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC

2.1.1.43) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC

2.1.1.43) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC

2.1.1.43) – Companies Involved in Therapeutics Development

Constellation Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Domainex Ltd

Epizyme Inc

Eternity Bioscience Inc

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

Ionis Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

Kainos Medicine Inc

OncoFusion Therapeutics Inc

Pfizer Inc

Transgene Biotek Ltd

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC

2.1.1.43) – Drug Profiles

CPI-0209 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPI-1205 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPI-169 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBI-2554 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-343 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-97594 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONISEZH-22.5Rx – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JQEZ-5 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KM-301 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-1943 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORS-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06821497 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-2554 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EZH1 and EZH2 for Leukemia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EZH2 for Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EZH2 for Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EZH2-EED for Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazemetostat hydrobromide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBL-0404 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valemetostat – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC

2.1.1.43) – Dormant Products

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC

2.1.1.43) – Discontinued Products

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC

2.1.1.43) – Product Development Milestones

Featured News & Press Releases

Feb 14, 2020: Epizyme announces FDA acceptance of New Drug Application for filing with priority review for TAZVERIK (tazemetostat) for the treatment of Follicular Lymphoma

Jan 24, 2020: Epizyme’s Tazverik receives accelerated approval from FDA

Dec 18, 2019: Epizyme submits new drug application to the U.S. FDA for Tazemetostat for the treatment of patients with follicular lymphoma

Dec 18, 2019: Epizyme (EPZM) trading of stock halted; Oncology drug advisory committee to review Tazemetostat

Dec 18, 2019: Epizyme announces FDA Advisory Committee votes unanimously in favor of Tazemetostat for the treatment of patients with epithelioid sarcoma

Dec 11, 2019: Daiichi Sankyo initiates Phase II study of valemetostat to treat ATL

Dec 09, 2019: Researchers create a potential therapy for deadly Breast Cancer that has few treatment options

Dec 07, 2019: Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma

Dec 02, 2019: Epizyme announces FDA Advisory Committee Meeting to review Tazemetostat for the treatment of patients with epithelioid sarcoma

Nov 06, 2019: Daiichi Sankyo showcases data presentations on valemetostat at American Society of Hematology (ASH)

Oct 30, 2019: Epizyme announces positive pre-NDA meeting for Tazemetostat for Follicular Lymphoma

Sep 24, 2019: Constellation Pharmaceuticals advances CPI-0209 into Clinical Trials, expanding its EZH2 franchise

Jul 25, 2019: Epizyme announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma

Jun 24, 2019: Epizyme reports positive data from trial of FL therapy tazemetostat

Jun 12, 2019: Epizyme announces conference call to discuss phase 2 Tazemetostat follicular lymphoma data

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Constellation Pharmaceuticals Inc, H1 2020

Pipeline by Daiichi Sankyo Co Ltd, H1 2020

Pipeline by Domainex Ltd, H1 2020

Pipeline by Epizyme Inc, H1 2020

Pipeline by Eternity Bioscience Inc, H1 2020

Pipeline by GlaxoSmithKline Plc, H1 2020

Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020

Pipeline by Ionis Pharmaceuticals Inc, H1 2020

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020

Pipeline by Kainos Medicine Inc, H1 2020

Pipeline by OncoFusion Therapeutics Inc, H1 2020

Pipeline by Pfizer Inc, H1 2020

Pipeline by Transgene Biotek Ltd, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports